George, Chief Business Officer for IACTA, overseeing business development, corporate development and capital raising, is a seasoned life sciences industry executive. He has founded and/or led multiple companies, including Scilex Pharmaceuticals, Inc., where he was Co-Founder and President, Business, and led the company through development, clinical trials, NDA submission, FDA approval, $140 million financing and commercial launch of the company’s first FDA-approved drug product. George has also held various other senior management positions, including Board Director, Managing Director, Chief Administrative Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded and private, global biotechnology and pharmaceutical companies, including Sorrento Therapeutics, Inc. (NASDAQ: SRNE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). In these roles, George helped lead the development and commercialization efforts and launches of multiple pharmaceutical drug products. Previously, in private practice, George was a partner in two AMLAW 200 law firms, where he had leadership roles, including establishing the life sciences practice group for one firm and heading it as the national co-chair. Additionally, George is a current member of the Board of Directors for multiple companies, including Morphogenesis, Inc. and Calidi Biotherapeutics, Inc.
George earned a Juris Doctor (JD) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (BAS) dual degree in Biochemistry & Economics from the University of California, Davis.